No Time to (Meno) Pause
A not-too-medical, evidence-based playbook for perimenopause → menopause → postmenopause. Practical, readable, and appointment-ready.
What this is (and what it's not)
This cheat sheet is designed to help you recognize patterns, rule out common mimics, and get an actual plan from your clinician. It's not a DIY prescription.
Fast definitions:
Perimenopause = the transition years where hormones fluctuate and symptoms can show up (often before periods fully stop).
Menopause = officially, 12 months with no period (not due to pregnancy/other causes).
Postmenopause = everything after menopause.
GSM (genitourinary syndrome of menopause) = vaginal + urinary symptoms driven by low estrogen (dryness, burning, pain with sex, recurrent UTIs, urgency).
Source: The Menopause Society (NAMS) patient education. Perimenopause | GSM PDF
What the evidence is strongest for
- Hormone therapy is the most effective option for hot flashes/night sweats and GSM, and helps prevent bone loss in appropriate candidates (individualized by history, age/timing, route). NAMS 2022
- Non-hormonal prescriptions can help hot flashes if you can't/don't want hormones. NAMS 2023
- Exercise + sleep + alcohol reduction aren't glamorous, but they're high ROI for symptom tolerance and long-term health.
Symptoms (what counts — beyond hot flashes)
People expect heat + missed periods. They don't expect the rest of the circus.
Common perimenopause pattern
- Periods start getting weird: shorter/longer cycles, skipped cycles, heavier/lighter bleeding.
- Vasomotor: hot flashes and/or night sweats.
- Sleep: trouble falling asleep, staying asleep, or waking too early.
- Mood + brain: irritability, anxiety, low mood, "brain fog."
- Body: joint aches, fatigue, headache/migraine changes.
- GSM can start in peri: dryness, pain with sex, urinary urgency/recurrent UTIs.
Symptom lists overlap with many conditions. The practical move is: treat what's likely, while also checking common mimics (thyroid, iron deficiency, sleep apnea, depression/anxiety, medication side effects). Source: NAMS perimenopause overview. NAMS
Red flags (don't label these "just menopause")
Get evaluated promptly if you have:
- Bleeding after menopause (after 12 months with no period)
- Very heavy bleeding, bleeding >7 days, bleeding between periods, or cycles <21 days apart
- New chest pain, fainting, severe shortness of breath, or persistent/worsening palpitations
- New neurologic symptoms (weakness, facial droop, severe sudden headache)
Heavy bleeding guidance: ACOG
Your 2–4 week plan (simple, effective)
Step 1: Track like it's a case file
- Hot flashes/night sweats: # per day and # nights/week
- Sleep: hours + "how wrecked am I?" rating (0–10)
- Mood: daily rating (0–10) + what triggers spikes
- Cycle: first day of bleeding, duration, heaviness (pads/tampons per day)
- GSM: dryness/pain (0–10), urinary symptoms (Y/N)
Step 2: Run two quick experiments
- Alcohol pause: try 2–3 weeks off (or a major cut) and compare hot flashes + sleep.
- Cooling + sleep tightening: layered bedding, fan, consistent wake time, reduce late caffeine.
Step 3: Decide your "first lever"
- If VMS is dominant → consider HT discussion (if eligible) or non-hormonal options. NAMS 2022 · NAMS 2023
- If GSM is dominant → ask specifically about local therapies (often under-used). NAMS 2022
- If bleeding/fatigue is dominant → ask about iron deficiency (CBC + ferritin) and bleeding work-up. ACOG
This structure turns "I feel unhinged" into a clinician-friendly problem statement with measurable outcomes.
Tests that matter more than chasing hormone levels
In most cases, perimenopause is a clinical diagnosis (age + symptoms + cycle changes), because hormones fluctuate — a single estrogen/FSH value can be misleading. NAMS 2022
Baseline checks worth discussing
- Blood pressure (it changes treatment options and risk)
- Lipids and glucose/A1c (cardiometabolic baseline)
- CBC + ferritin/iron if heavy/closer-together periods or fatigue/shortness of breath (iron deficiency is common and fixable). ACOG
- TSH if symptoms overlap (fatigue, palpitations, significant cycle changes). NIDDK
- Bone health: if you have risk factors (see below), ask when a DXA scan makes sense (timing depends on history).
Actionable numbers (so you know what "normal" looks like)
| Measure | Useful "baseline" target (typical adults) | When to check / ask for it |
|---|---|---|
| Blood pressure | Home average <135/85; persistent averages above this = worth discussing. (Office thresholds differ.) | At least yearly; sooner if headaches, palpitations, strong family history, pregnancy history, or before starting certain meds. |
| Lipids | Know: LDL-C, non‑HDL‑C, triglycerides; consider ApoB (and Lp(a) once in a lifetime). | Often start screening: men ≥40; women ≥50 or postmenopausal (earlier with risk factors). Repeat interval depends on risk. |
| Glucose / A1c | A1c: normal typically <6.0%; "higher risk" 6.0–6.4%; diabetes ≥6.5 (confirm per clinician/lab). Fasting glucose: diabetes ≥7.0 mmol/L. | Screen at least every 3 years from ~40 (earlier if overweight, family history, gestational diabetes, PCOS, etc.). |
| Ferritin (iron stores) | In adults, iron deficiency is unlikely if ferritin >30 µg/L (higher cutoffs may apply with inflammation). Heavy/close periods + fatigue = classic setup. | Check if heavy bleeding, fatigue, hair shedding, restless legs, shortness of breath, or low endurance. |
Bone health: risk factors women often miss
If you have any of these, ask when a bone mineral density (DXA) scan makes sense (often earlier than you think).
- Low-trauma ("fragility") fracture after age 40
- Parent with hip fracture
- Long-term glucocorticoids (e.g., prednisone ≥3 months)
- Smoking
- High alcohol intake (≈3+ drinks/day most days)
- Low body weight / significant weight loss
- Rheumatoid arthritis or conditions/meds linked to bone loss
- Early menopause / prolonged low estrogen states
Who should get a baseline DXA? Examples include: all adults ≥70; postmenopausal women 65–69 with ≥1 risk factor; postmenopausal women 50–64 with prior low-trauma fracture or ≥2 risk factors. Osteoporosis Canada
Sources for the above ranges: Hypertension Canada guidance; Canadian Cardiovascular Society dyslipidemia guideline; Diabetes Canada diagnostic criteria; BC iron deficiency guideline; Osteoporosis Canada. Links are in Receipts.
Quick "symptom → test" map
| Symptom cluster | Common mimics / contributors to rule out | What to ask about |
|---|---|---|
| Heavy bleeding + fatigue | Iron deficiency, thyroid, fibroids/structural issues | CBC + ferritin/iron; bleeding evaluation as appropriate |
| Palpitations + anxiety | Thyroid issues, anemia, stimulants, panic disorder, arrhythmia | TSH; CBC/ferritin if bleeding; consider ECG if persistent |
| Insomnia | Sleep apnea, restless legs, alcohol/caffeine, mood disorder | Screen for apnea; iron if restless legs + low ferritin suspicion |
| Brain fog / low mood | Depression/anxiety, sleep deprivation, thyroid, B12 deficiency | Discuss screening tools; consider TSH/B12 if risk factors |
Treatment menu (broad, practical)
1) Lifestyle + symptom supports (low risk, often helpful)
- Cooling strategy: layered clothes, breathable bedding, fan, "cooling kit."
- Exercise: aerobic + resistance training helps mood, sleep, bone, metabolic health. Adult activity guidelines: CDC
- Sleep: consider CBT-I if insomnia is dominant (often more effective than supplements).
- GSM basics: vaginal moisturizers + lubricants; pelvic floor physio when pain/tightness is part of the story.
2) Non-hormonal prescription options (especially for hot flashes)
- SSRIs/SNRIs (selected agents), gabapentin, clonidine, and newer NK3 receptor antagonists. Guideline overview: NAMS 2023
- Example: fezolinetant (Veozah) is FDA-approved for moderate-to-severe hot flashes. FDA summary
3) Hormone therapy (HT / MHT)
- Most effective for VMS and GSM; also helps prevent bone loss in appropriate candidates. NAMS 2022
- Route matters: patch/gel (transdermal) vs pill (oral) can matter for risk profile; clinician will individualize.
- If you have a uterus, you usually need endometrial protection (progestogen/progesterone or alternatives).
4) Local vaginal options for GSM (often the "why did no one tell me this exists?" category)
- Low-dose vaginal estrogen (cream/tablet/ring) and other options depending on your situation. NAMS 2022
If you want the deeper HT breakdown (routes, myths, who should avoid/caution, questions to ask), use your companion cheat sheet: Hormone Therapy: Say What Now?
Supplements (transparent take)
Supplements aren't first-line menopause treatment in major guidelines, but some can be useful for specific targets (sleep, stress, deficiencies) — if you treat them like an experiment.
The Menopause Society's 2023 nonhormone statement does not recommend most supplements/herbal remedies for vasomotor symptoms because evidence is limited/variable and products aren't standardized. NAMS 2023
High-ROI, low-drama basics
- Creatine monohydrate: generally 3–5 g/day for training support (not a menopause-specific cure; useful if strength is a goal).
- Vitamin D: if low/at risk — discuss testing and dosing with clinician. NIH ODS
- Magnesium (sleep/anxiety support): start with magnesium glycinate / bisglycinate providing 200–350 mg/day of elemental magnesium, taken 1–2 hours before bed for 2–4 weeks. If it helps, keep; if not, stop. Do not exceed 350 mg/day of magnesium from supplements unless your clinician says otherwise (GI side effects + higher-risk with kidney disease). NIH ODS · Sleep RCTs: Abbasi 2012 (PMC) · Schuster 2025 (PMC)
- Iron: only if deficiency confirmed (don't guess; test first).
Adaptogens (when the main issue is stress/sleep — not hot flashes)
Dr. Stacy Sims often mentions adaptogens as optional tools for stress resilience + sleep support. They are not a Menopause Society–recommended treatment for vasomotor symptoms (hot flashes/night sweats), because evidence is limited and products vary.
Before you buy anything: pick one target (sleep latency, night wakings, anxiety, daytime fatigue), track it, and run a 6–8 week experiment. If you stack five new things and feel "better," you learned nothing.
| Adaptogen | Best evidence for | Typical studied dose window | Reality check |
|---|---|---|---|
| Ashwagandha (Withania somnifera) | Stress/anxiety reduction; some sleep outcomes | Often 250–600 mg/day standardized extract for 6–8 weeks | Most consistent human data among common adaptogens (still not "menopause treatment"). Evidence summary + dosing/safety: NIH ODS · NCCIH: Link |
| Holy Basil / Tulsi (Ocimum tenuiflorum) | Stress reduction; improved subjective sleep quality in stressed adults | 250 mg/day standardized extract for 8 weeks (125 mg twice daily) | Promising RCT signal for stress + sleep (not menopause-specific): Lopresti 2022 (PMC) |
| Rhodiola rosea | Stress-related fatigue, burnout-type symptoms; some performance/fatigue measures | Commonly 200–600 mg/day extract (varies by prep) for 4–12 weeks | Evidence base is heterogeneous (different products/doses/endpoints). Clinical overview: Stojcheva 2022 (PMC) |
| Maca (Lepidium meyenii) | Small RCTs suggest possible improvement in some menopausal symptom scores (esp mood/sexual well-being) | Often 1.5–3 g/day powder/extract in trials (varies) | Evidence is limited/small; quality varies. Reviews: PMID 21840656 · Mehrnoush 2021 |
| Schisandra (Schisandra chinensis) | Fatigue/stress markers in small human studies | Example trial: ~1,000 mg/day extract (varies) | Early/small human data — treat as "optional experiment," not a guarantee: PMID 32201331 |
Sims mentions adaptogens like these as options for some women (especially around stress + sleep): maca, ashwagandha, schisandra, rhodiola, holy basil (and others). Example: Triathlete "Ask Stacy"
Myths (don't get played)
- "Bioidentical" automatically means safer. Not automatically. Some FDA-approved hormones are bioidentical; the bigger issue is compounded custom mixes/pellets with variable dosing/quality and limited safety data vs approved products. ACOG 2023
- Natural / plant-based hormones are "less chemical." They are still chemicals; "natural" describes the source, not safety or appropriate dosing. (Counseling overview: PMC)
- You need a custom hormone panel to treat menopause. Usually false. Fluctuation makes single lab values unreliable; treatment is typically symptom + history driven. NAMS 2022
Receipts (key links)
- NAMS 2022 Hormone Therapy Position Statement: PMID 35797481
- NAMS 2023 Nonhormone Therapy Position Statement: PMID 37252752
- NAMS patient page (perimenopause): Link
- NAMS GSM MenoNote (PDF): PDF
- ACOG: Heavy menstrual bleeding: Link
- ACOG 2023: Compounded "bioidentical" MHT: Link
- CDC adult activity guidelines: Link
- NIH ODS: Ashwagandha: Link
- NIH ODS: Vitamin D: Link
- Hypertension Canada guidance (home/office thresholds; treatment targets): Link
- Canadian Cardiovascular Society dyslipidemia guideline (screening + ApoB/Lp(a)): Link
- Diabetes Canada diagnostic criteria (A1c/FPG) + screening: Guidelines · A1c explainer: HealthLinkBC
- BC Guideline: Iron deficiency diagnosis & ferritin cutoffs: Link
- CMAJ 2025: Iron deficiency in females (ferritin thresholds): Link
- Osteoporosis Canada: Risk factors: Link · Who should get BMD testing: Link
- NIH ODS: Magnesium (UL 350 mg supplemental): Link
- Holy Basil RCT (stress + sleep): Lopresti 2022 (PMC)
- Rhodiola clinical evidence overview: Stojcheva 2022 (PMC)
- Magnesium bisglycinate sleep RCT: Schuster 2025 (PMC)
- Sims (adaptogens mentioned): Triathlete "Ask Stacy"
Disclaimer: Educational only. Not medical advice. If you have red flags or complex history, involve a licensed clinician.